

Bridge biotec to present at Biotech Showcase™ 2019 in San Francisco

Macclesfield UK / 1.3.19 – Bridge Biotec today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.

Dr. Mike Davies will present at Biotech Showcase™ as follows:

Date: January 7, 2019

Time: 11:00 (PST)

Room: Franciscan B (Ballroom B)

Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA (United States)

About Bridge & our presentation

Bridge Biotec Limited ("Bridge") is developing novel, nano-particle delivered peptide therapeutics to safely treat life threatening and disabling inflammatory conditions such as inflammatory bowel disease (IBD), atopic dermatitis (AD, eczema), psoriasis and burns to cure serious inflammatory diseases.

Inflammation refers to a biological response to stimuli, interpreted by the body to have a potentially harmful effect. In certain situations, such as after injury, inflammation is a normal response. However, inflammatory diseases result in the immune system attacking the body's own cells or tissues and may cause abnormal inflammation resulting in chronic pain, swelling, stiffness and damage to normal tissues.

Bridge Biotec's novel medicines are short proteins ("peptides") that can be delivered into the human cell using a patented safe nano-polymer delivery technology which have been shown to switch off inflammation in a recognised cellular model. These short peptides, that will be broken down into simple and naturally occurring amino acids, are highly active and exquisitely specific inflammation blockers, so only tiny doses will be required to cure serious inflammatory diseases.

Leadership quote

"I am delighted to be sharing our exciting pre-clinical results demonstrating that our nano-particle delivered peptides switch off inflammation in a recognised human cellular model. We are now looking for a further investment of \$16m to drive the lead compound (JEL3108) through to approved IND over the next three years"

Dr. Mike Davies, Founder & Chief Executive Officer of Bridge Biotec Limited.

Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

"We are delighted that Bridge Biotec will be presenting at Biotech Showcase this year," said Sara Demy, CEO of Demy-Colton. "Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. We are thrilled to, once again, be hosting what we believe will be the great strategic networking opportunity of 2019."

continued over page

Michael J Davies MD, FRCS (Engl., Ed), FRCPSG

Chief Executive Officer & Founder

UK: +44 2030971979

US: +1 212 863 9902

Mike.Davies@bridgebiotec.com

www.bridgebiotec.com

Bridge Biotec Limited, The BioHub at Alderley Park, Mereside, Alderley Park, Macclesfield, SK10 4TG

Bridge Biotec is a limited company incorporated in England with registered number 10469714.



ABOUT BIOTECH SHOWCASE

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its eleventh year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.

ABOUT BRIDGE BIOTEC

Bridge Biotec Limited ("Bridge") is developing novel, nano-particle delivered peptide therapeutics to safely treat life threatening and disabling inflammatory conditions such as inflammatory bowel disease (IBD), atopic dermatitis (AD, eczema), psoriasis and burns to cure serious inflammatory diseases.

Contacts

Bridge Biotec Ltd.
The BioHub at Alderley Park
Mersey, Alderley Park
Macclesfield
SK10 4TG

Email: contact@bridgebiotec.com
UK: +44 (0) 20 3097 1979
US: +1 212 863 9902

Follow Bridge Biotec on:
Twitter at [@bridgebiotec](https://twitter.com/bridgebiotec)
LinkedIn: [linkedin.com/company/bridge-biotec/](https://www.linkedin.com/company/bridge-biotec/)
Facebook: [facebook.com/bridgebiotec/](https://www.facebook.com/bridgebiotec/)

Follow Biotech Showcase on Twitter at [@EBDGroup](https://twitter.com/EBDGroup) and [@Demy_Colton](https://twitter.com/Demy_Colton) and tag your posts with [#BiotechShowcase](https://twitter.com/hashtag/BiotechShowcase).